Enterprise-Grade Quality. Without the Enterprise Price Tag.
GMP quality depth without enterprise complexity or cost. Built for mid-market pharma — typically $50M–$500M revenue across 2–5 sites, where VP Quality and IT buy together. Phase 1 GMP Core is in design-partner validation today.
What Teams Face Today
Mid-market pharma with multi-site GMP operations, caught between tools that don't scale and enterprise platforms that consume too many resources.
Enterprise Platform Cost
Legacy platforms priced for Fortune 500 pharma. Licensing, implementation, and maintenance exceed mid-market budgets.
Resource Constraints
Lean QA teams managing growing regulatory obligations across 2–5 GMP sites with manual processes and spreadsheet tracking.
Validation Burden
CSV and GAMP 5 documentation that consumes months of QA bandwidth before a platform is operational.
Scalability Gaps
Outgrowing point solutions but unable to justify full enterprise platform deployments.
The Verixa Advantage
We bridge the gap — delivering enterprise-grade GMP quality in a platform priced and scoped for the mid-market.
Phase 1 GMP Core scoped for mid-market pharma running 2–5 sites — typically $50M–$500M revenue, with a VP Quality and IT as joint buyers. Currently in design-partner validation.
Right-Sized for Multi-Site GMP
Right-Sized for the Mid-Market
Priced by workflow
USD-denominated. License the workflows you need; a Multi-Workflow / Multi-Site Agreement covers larger deployments. Not by seat count. Confirmed after design-partner validation. See the Pricing page.
Priced by workflow
INR-denominated, scoped per deployment. Not by seat count. Confirmed after design-partner validation. See the Pricing page.
Which workflow should Verixa map first?
Select one current quality process. We will show how Verixa could support it, where AI assists, where human decisions remain mandatory, and what validation responsibilities stay with your organization.